March 21, 2026. More for You ...

11.4 percent of adults aged 65 to 79 years with stage 1 hypertension would not be eligible under 2025 criteria.

Red Roof’s 2025 results, announced this week, tell a story that’s becoming increasingly familiar across hospitality: even in ...

An analysis of the 2025 AHA/ACC hypertension guidelines found that under the new guidelines, about 11% of adults ages 65 to ...

Detailed price information for Mineralys Therapeutics Inc (MLYS-Q) from The Globe and Mail including charting and trades.

Mineralys Therapeutics (NASDAQ:MLYS) used its fourth-quarter and full-year 2025 earnings call to highlight a key regulatory ...

Announced FDA acceptance of NDA for lorundrostat in adults with hypertension; assigned PDUFA target date of December 22, 2026 –– Conference ...

An organization founded in 1982 by the late Greg Schilling continues to be a force in the Woodland Park/Teller County community. Today, Help the Needy, HtN, is a source of connection to those needing ...

The FDA accepts the NDA for lorundrostat, a selective aldosterone synthase inhibitor, for adults with uncontrolled or resistant hypertension.

A pooled SPYRAL HTN analysis (n = 2,137) showed sustained blood pressure reductions through 3 years after Symplicity Spyral renal denervation. A separate pooled analysis found a 42% reduction in ...

Medtronic today shared new, long-term data demonstrating the clinical benefit of its Symplicity Spyral renal denervation (RDN) system.